News and Announcements
INOPTEC delivered 400% ROI
- Published April 21, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The “Innovator of the Year” awarded INOPTEC has just raised 250k EUR from a strategic plastic part supplier this week, on top of the 1 Mio. EUR which was already raised.
INOPTEC has developed and patented the world’s first Vision Enhancement System (VES), which comprises smart glasses and LED lamps, enabling instant light adaptation & protection – day or night – to improve the wearer’s safety and performance under otherwise impossible and dangerous viewing/light conditions!
UK Policy:
PA Consulting Group (R&D firm Cambridge) and Kinnier Dufort (Design firm Bristol) are still set as top-notch development partners for the British-German high-tech start-up INOPTEC Ltd. – even after Brexit, says the founder and CEO, Ralf G.J. Knoll.
We can maximise our R&D and marketing abilities by combining our UK tech clusters with those in Germany, Ireland and the US.
And with 80 patents underway – we can create a worldwide monopoly!
Smart glass users can go beyond themselves – and become unstoppable!
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
